<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942017000300003</article-id>
<article-id pub-id-type="doi">10.30827/ars.v58i3.6527</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio bibliométrico sobre el impacto de los medicamentos biosimilares]]></article-title>
<article-title xml:lang="en"><![CDATA[Bibliometric Study About the Impact of Biosimilars Drugs]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peralta]]></surname>
<given-names><![CDATA[Sebastián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[Maria Encarnación]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[Maria Adolfina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Granada Facultad de Farmacia Departamento de Farmacia y Tecnología Farmacéutica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<volume>58</volume>
<numero>3</numero>
<fpage>103</fpage>
<lpage>106</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942017000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942017000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942017000300003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivos: La bibliometría es un tipo de estudio estadístico sobre datos científicos. Mediante esta herramienta queremos valernos para visualizar distintos aspectos que presentan los medicamentos biosimilares, su importancia y el impacto que generan en su entorno.  Métodos: se ha utilizando como motor de búsqueda Science Direct, así como de publicaciones científicas referenciadas en la bibliografía y como de algunas webs sobre la materia.  Resultados: Casi todos los indicadores señalan la gran importancia económica que concierne entorno a los medicamentos biosimilares, la actualidad que presenta y que gran parte de su estudio se concentra alrededor de los pacientes.  Conclusiones: Con este trabajo se comprueba el gran interés que ofrecen los biosimilares y sobre todo el impacto que tendrán en un futuro, así como las repercusiones que traerán consigo, sobre todo en los campos económicos y de la salud.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Objectives: A bibliometrics study is a type of statistical study on scientific data. With this tool we want to visualize different aspects of biosimilar drugs, their importance and the impact they generate in their environment.  Methods: Science Direct was utilized as a search engine, in addition to the scientific publications referenced in the bibliography as well as some websites concerning the subject.  Results: Almost all the indicators point to the great economic importance of biosimilar drugs, their novelty and their patient-coentered focus.  Conclusions: It is of great interest to know the future impact that these medicines will have and the repercussions they will bring, especially in the economic and health fields.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Medicamentos biológicos]]></kwd>
<kwd lng="es"><![CDATA[medicamentos biosimilares]]></kwd>
<kwd lng="es"><![CDATA[impacto económico]]></kwd>
<kwd lng="en"><![CDATA[Biological drugs]]></kwd>
<kwd lng="en"><![CDATA[biosimilars drugs]]></kwd>
<kwd lng="en"><![CDATA[economic impact]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mingersa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Leydesdorffb]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of theory and practice in scientometrics]]></article-title>
<source><![CDATA[Eur J Oper Res]]></source>
<year>2015</year>
<volume>246</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-19</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zúñiga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la biosimilitud y comparabilidad de medicamentos biosimilares]]></article-title>
<source><![CDATA[Ars Pharm]]></source>
<year>2013</year>
<volume>54</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>32-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villamañán]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Armada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ruano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Sala]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Herrero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Juego de patentes. Sobre medicamentos genéricos y biosimilares. The patents game. Generic and biosimilar drugs]]></article-title>
<source><![CDATA[Rev Calid Asist]]></source>
<year>2016</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-105</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schimizzi]]></surname>
<given-names><![CDATA[G.F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biosimilars from a practicing rheumatologist perspective: An overview]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2016</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>911-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flyvbjerg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomathematics. Mathematics of Biostructures and Biodynamics]]></article-title>
<source><![CDATA[Chem Phys Lipids]]></source>
<year>2000</year>
<volume>106</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-2</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romain]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Preud'homme]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualités pharmaceutiques]]></article-title>
<source><![CDATA[Arch Pediatr]]></source>
<year>2007</year>
<volume>14</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1274-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Blog biosim</collab>
<source><![CDATA[Asociación Española de biosimilares]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Girault]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Trouvin]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Blachier-Poisson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gary]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Laloye]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biosimilars: from Technical to Pharmacoeconomic Considerations]]></article-title>
<source><![CDATA[Ther]]></source>
<year>2015</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-55</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khraishi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stead]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lukas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scotte]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biosimilars: A Multidisciplinary Perspective]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2016</year>
<volume>38</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1238-49</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curigliano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Darran]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biosimilars: Extrapolation for oncology]]></article-title>
<source><![CDATA[Oncol Hematol]]></source>
<year>2016</year>
<volume>104</volume>
<page-range>131-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cochran]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Superti-Furga]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crews]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Where is the Future of Drug Discovery for Cancer?]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2017</year>
<volume>168</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>564-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
